Liquidia (NASDAQ:LQDA) Earns “Buy” Rating from HC Wainwright

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $32.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 156.62% from the stock’s current price.

Several other analysts have also recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Liquidia in a report on Monday, June 3rd. Oppenheimer began coverage on Liquidia in a research note on Tuesday, June 25th. They set a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.60.

Liquidia Stock Performance

Shares of LQDA stock opened at $12.47 on Wednesday. The stock’s fifty day moving average is $12.74 and its 200-day moving average is $13.42. The stock has a market capitalization of $952.88 million, a PE ratio of -7.99 and a beta of 0.32. Liquidia has a 52 week low of $5.71 and a 52 week high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.22). The business had revenue of $2.97 million for the quarter, compared to the consensus estimate of $4.31 million. Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. As a group, analysts forecast that Liquidia will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several large investors have recently made changes to their positions in LQDA. American International Group Inc. lifted its stake in Liquidia by 5.2% in the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock valued at $366,000 after buying an additional 1,215 shares during the period. Bleakley Financial Group LLC lifted its stake in Liquidia by 6.6% in the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock valued at $490,000 after buying an additional 2,057 shares during the period. Fortitude Family Office LLC acquired a new position in Liquidia in the fourth quarter valued at about $26,000. SG Americas Securities LLC lifted its stake in Liquidia by 17.4% in the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock valued at $187,000 after buying an additional 2,298 shares during the period. Finally, Hilltop National Bank acquired a new position in Liquidia in the second quarter valued at about $33,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).